相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HLA-associated antiepileptic drug-induced cutaneous adverse reactions
Kerry A. Mullan et al.
HLA (2019)
Potential biomarker of fibroblast growth factor 21 in valproic acid-treated livers
Xiaoxiao Xu et al.
BIOFACTORS (2019)
Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update
Hong-Li Guo et al.
CURRENT PHARMACEUTICAL DESIGN (2019)
Effects of levetiracetam and valproic acid treatment on liver function tests, plasma free carnitine and lipid peroxidation in childhood epilepsies
Pinar Haznedar et al.
EPILEPSY RESEARCH (2019)
Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis
Guangyan Mu et al.
PHARMACOGENOMICS (2019)
Medication adherence and adverse effect profile of antiepileptic drugs in Nigerian patients with epilepsy
Joseph O. Fadare et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2018)
Metabolic Dysfunction and Oxidative Stress in Epilepsy
Jennifer N. Pearson-Smith et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in a Chinese Tibetan population
Li Wang et al.
MEDICINE (2017)
Role of Nrf2 activation and NF-κB inhibition in valproic acid induced hepatotoxicity and in diammonium glycyrrhizinate induced protection in mice
Jing Jin et al.
FOOD AND CHEMICAL TOXICOLOGY (2014)
Valproic Acid and Fatalities in Children: A Review of Individual Case Safety Reports in VigiBase
Kristina Star et al.
PLOS ONE (2014)
Adverse drug reactions induced by valproic acid
Radu M. Nanau et al.
CLINICAL BIOCHEMISTRY (2013)
Toxicity of valproic acid in isolated rat liver mitochondria
Iman Jafarian et al.
TOXICOLOGY MECHANISMS AND METHODS (2013)
Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases
Junji Saruwataria et al.
EPILEPSY RESEARCH (2012)
Assessment of the role of in situ generated (E)-2,4-diene-valproic acid in the toxicity of valproic acid and (E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes
Jayakumar Surendradoss et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2012)
Determinants of health-related quality of life in pharmacoresistant epilepsy: Results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments
Chiara Luoni et al.
EPILEPSIA (2011)
A comparative study of serum F protein and other liver function tests as an index of hepatocellular damage in epileptic patients
N. Callaghan et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia
Mariko Yagi et al.
PEDIATRICS INTERNATIONAL (2010)
Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment
G. Luef et al.
EPILEPSY RESEARCH (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes are risk factors for increased serum γ-glutamyltransferase in valproic acid-treated patients
Yumi Fukushima et al.
CLINICA CHIMICA ACTA (2008)
Protein C, protein S and other pro- and anticoagulant activities among epileptic children using sodium valproate
Meltem Ugras et al.
BRAIN & DEVELOPMENT (2006)
Pro- and anticoagulatory factors under sodium valproate-therapy in children
MC Banerjea et al.
NEUROPEDIATRICS (2002)
Children versus adults: Pharmacokinetic and adverse-effect differences
GD Anderson
EPILEPSIA (2002)
Pharmacological and therapeutic properties of valproate - A summary after 35 years of clinical experience
E Perucca
CNS DRUGS (2002)
Low serum biotinidase activity in children with valproic acid monotherapy
KH Schulpis et al.
EPILEPSIA (2001)
分享论文
